InnoCare Pharma Limited (9969.HK) HKSE

14.73

+0.65(+4.62%)

Updated at April 24 01:59PM

Currency In HKD

Key Executives

Name	Title	Pay	Year Born
Jisong Cui	Co-Founder, Chairwoman & Chief Executive Officer	9.4M	1963
Renbin Zhao	Senior Vice President of Clinical Development & Medical Research and Executive Director	3.76M	1969
Bei Yuan	Secretary of the Board	0	N/A
Xiangyang Chen	Chief Technology Officer	0	1967
Junjian Liu	Senior Vice President of Biology & Biologics	0	N/A
Davy Ouyang	VP & Head of Biology	0	N/A
Jeff Chen	Chief Commercial Officer	0	N/A
Nan Gao	Chief Operating Officer	0	1974
Xin Fu	Chief Financial Officer	0	1978
Junsu Wang	General Counsel	0	1977
Yue Tan	Accounting Supervisor	0	N/A

Name

Title

Pay

Year Born

Jisong Cui

Co-Founder, Chairwoman & Chief Executive Officer

9.4M

1963

Renbin Zhao

Senior Vice President of Clinical Development & Medical Research and Executive Director

3.76M

1969

Bei Yuan

Secretary of the Board

N/A

Xiangyang Chen

Chief Technology Officer

1967

Junjian Liu

Senior Vice President of Biology & Biologics

N/A

Davy Ouyang

VP & Head of Biology

N/A

Jeff Chen

Chief Commercial Officer

N/A

Nan Gao

Chief Operating Officer

1974

Xin Fu

Chief Financial Officer

1978

Junsu Wang

General Counsel

1977

Yue Tan

Accounting Supervisor

N/A

Description

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189, ICP-915, and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.